+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gene Therapy Market Size, Share & Trends Analysis Report by Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), by Vector Type, by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4808538
  • Report
  • February 2020
  • Region: Global
  • 160 Pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Audentes Therapeutics
  • Bluebird Bio, Inc.
  • Gensight Biologics S.A.
  • Orchard Therapeutics
  • Sanofi
  • Spark Therapeutics, Inc.
  • MORE
The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.

Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia, indicates the shift in preferences of companies toward other untapped segments.

Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.

Further key findings from the study suggest:
  • Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors
  • In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA
  • Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma
  • North America dominated the global gene therapy market in 2019 as the U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in the U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America
  • Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation
  • These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics’ Luxturna for selling the product outside the U.S.'

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Audentes Therapeutics
  • Bluebird Bio, Inc.
  • Gensight Biologics S.A.
  • Orchard Therapeutics
  • Sanofi
  • Spark Therapeutics, Inc.
  • MORE
Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation

Chapter 3 Gene Therapy Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust gene therapy pipeline
3.1.1.2 Introduction of technological advancements
3.1.1.3 Increasing investment from the companies and partnerships
3.1.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.2.2 High prices of gene therapy medicines
3.1.3 Opportunity analysis
3.1.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
3.1.3.2 Facility expansion for cell and gene therapies
3.1.3.3 Technological advancements in manufacturing vectors
3.1.4 Challenge Analysis
3.1.4.1 Production capacity challenges
3.1.4.2 Manufacturing challenges pertaining to large-scale production of vectors
3.1.5 Regulatory framework
3.2 Gene Therapy Market - SWOT Analysis, by Factor (Political & legal, economic and technological)
3.3 Industry Analysis - Porter’s
3.4 Pricing Analysis
3.5 Pipeline Analysis

Chapter 4 Gene Therapy Market Categorization: Indication Estimates & Trend Analysis
4.1 Gene Therapy Market: Indication Movement Analysis
4.2 Acute Lymphoblastic Leukemia (ALL)
4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2016 - 2027 (USD Million)
4.3 Inherited Retinal Disease
4.3.1 Global gene therapy market for inherited retinal disease, 2016 - 2027 (USD Million)
4.4 Large B-cell Lymphoma
4.4.1 Global gene therapy market for large B-cell lymphoma, 2016 - 2027 (USD Million)
4.5 Adenosine Deaminase (ADA)‐Deficient Severe Combined Immunodeficiency (SCID)
4.5.1 Global gene therapy market for ADA-SCID, 2016 - 2027 (USD Million)
4.6 Melanoma (Lesions)
4.6.1 Global gene therapy market for melanoma (lesions), 2016 - 2027 (USD Million)
4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2016 - 2027 (USD Million)
4.8 Head & Neck Squamous Cell Carcinoma
4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2016 - 2027 (USD Million)
4.9 Peripheral Arterial Disease
4.9.1 Global gene therapy market for peripheral arterial disease, 2016 - 2027 (USD Million)
4.10 Spinal Muscular Atrophy (SMA)
4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2016 - 2027 (USD Million)
4.11 Others
4.11.1 Global gene therapy market for other indications, 2016 - 2027 (USD Million)

Chapter 5 Gene Therapy Market Categorization: Vector Type Estimates & Trend Analysis
5.1 Gene Therapy Market: Vector Type Movement Analysis
5.2 Lentivirus
5.2.1 Global lentivirus-based gene therapy market, 2016 - 2027 (USD Million)
5.3 AAV
5.3.1 Global AAV-based gene therapy market, 2016 - 2027 (USD Million)
5.4 Retrovirus & Gammaretrovirus
5.4.1 Global Retrovirus & Gammaretrovirus vectors-based gene therapy market, 2016 - 2027 (USD Million)
5.5 Modified Herpes Simplex Virus
5.5.1 Global modified herpes simplex virus vectors-based gene therapy market, 2016 - 2027 (USD Million)
5.6 Adenovirus
5.6.1 Global adenovirus vectors-based gene therapy market, 2016 - 2027 (USD Million)
5.7 Non-viral Plasmid Vectors
5.7.1 Global non-viral plasmids-based gene therapy market, 2016 - 2027 (USD Million)

Chapter 6 Gene Therapy Market Regional Estimates & Trend Analysis, by Indication and Vector Type
6.1 Gene Therapy Market Share, by Region
6.2 North America
6.2.1 North America gene therapy market, 2016 - 2027 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. gene therapy market, by indication, 2016 - 2027 (USD Million)
6.2.2.2 U.S. gene therapy market, by vector type, 2016 - 2027 (USD Million)
6.2.3 Canada
6.2.3.1 Canada gene therapy market, by indication, 2016 - 2027 (USD Million)
6.2.3.2 Canada gene therapy market, by vector type, 2016 - 2027 (USD Million)
6.3 Europe
6.3.1 Europe gene therapy market, 2016 - 2027 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific gene therapy market, 2016 - 2027 (USD Million)
6.4.2 China
6.4.2.1 China gene therapy market, by indication, 2016 - 2027 (USD Million)
6.4.2.2 China gene therapy market, by vector type, 2016 - 2027 (USD Million)
6.4.3 Japan
6.4.3.1 Japan gene therapy market, by indication, 2016 - 2027 (USD Million)
6.4.3.2 Japan gene therapy market, by vector type, 2016 - 2027 (USD Million)
6.4.4 Russia
6.4.4.1 Russia gene therapy market, by indication, 2016 - 2027 (USD Million)
6.4.4.2 Russia gene therapy market, by vector type, 2016 - 2027 (USD Million)
6.4.5 Australia
6.4.5.1 Australia gene therapy market, by indication, 2016 - 2027 (USD Million)
6.4.5.2 Australia gene therapy market, by vector type, 2016 - 2027 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.1.1 Novartis AG
7.1.2 Bluebird bio, Inc.
7.1.3 Spark Therapeutics, Inc.
7.1.4 REGENXBIO, Inc.
7.1.5 Audentes Therapeutics
7.1.6 Voyager Therapeutics
7.1.7 REGENXBIO, Inc.
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Oxford BioMedica plc
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product benchmarking
7.1.8.4 Strategic initiatives
7.1.9 Voyager Therapeutics
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Human Stem Cells Institute
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking
7.1.10.4 Strategic initiatives
7.1.11 Dimension Therapeutics, Inc.
7.1.11.1 Company overview
7.1.11.2 Financial performance
7.1.11.3 Product benchmarking
7.1.11.4 Strategic initiatives
7.1.12 Bristol-Myers Squibb Company
7.1.12.1 Company overview
7.1.12.2 Financial performance
7.1.12.3 Product benchmarking
7.1.12.4 Strategic initiatives
7.1.13 Sanofi
7.1.13.1 Company overview
7.1.13.2 Financial performance
7.1.13.3 Product benchmarking
7.1.13.4 Strategic initiatives
7.1.14 Applied Genetic Technologies Corporation
7.1.14.1 Company overview
7.1.14.2 Financial performance
7.1.14.3 Product benchmarking
7.1.14.4 Strategic initiatives
7.1.15 Spark Therapeutics, Inc.
7.1.15.1 Company overview
7.1.15.2 Financial performance
7.1.15.3 Product benchmarking
7.1.15.4 Strategic initiatives
7.1.16 Bluebird Bio, Inc.
7.1.16.1 Company overview
7.1.16.2 Financial performance
7.1.16.3 Product benchmarking
7.1.16.4 Strategic initiatives
7.1.17 Novartis AG
7.1.17.1 Company overview
7.1.17.1.1 AveXis, Inc.
7.1.17.2 Financial performance (Novartis AG)
7.1.17.2.1 Financial performance (AveXis, Inc.)
7.1.17.3 Product benchmarking
7.1.17.4 Strategic initiatives (Novartis AG)
7.1.17.4.1 Strategic initiatives (AveXis, Inc.)
7.1.18 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
7.1.18.1 Company overview
7.1.18.2 Financial performance
7.1.18.3 Product benchmarking
7.1.18.4 Strategic initiatives
7.1.19 UniQure N.V.
7.1.19.1 Company overview
7.1.19.2 Financial performance
7.1.19.3 Product benchmarking
7.1.19.4 Strategic initiatives
7.1.20 Celgene Corporation
7.1.20.1 Company overview
7.1.20.2 Financial performance
7.1.20.3 Product benchmarking
7.1.20.4 Strategic initiatives
7.1.21 Shire Plc
7.1.21.1 Company overview
7.1.21.2 Financial performance
7.1.21.3 Product benchmarking
7.1.21.4 Strategic initiatives
7.1.22 Cellectis S.A.
7.1.22.1 Company overview
7.1.22.2 Financial performance
7.1.22.3 Product benchmarking
7.1.22.4 Strategic initiatives
7.1.23 Sangamo Therapeutics, Inc.
7.1.23.1 Company overview
7.1.23.2 Financial performance
7.1.23.3 Product benchmarking
7.1.23.4 Strategic initiatives
7.1.24 Orchard Therapeutics
7.1.24.1 Company Overview
7.1.24.2 Product Benchmarking
7.1.24.3 Strategic initiatives
7.1.25 Gilead Lifesciences, Inc.
7.1.25.1 Company Overview
7.1.25.2 Financial Performance
7.1.25.3 Product Benchmarking
7.1.25.4 Strategic initiatives
7.1.26 Benitec Biopharma
7.1.26.1 Company overview
7.1.26.2 Financial performance
7.1.26.3 Product benchmarking
7.1.26.4 Strategic initiatives
7.1.27 Sibiono GeneTech Co., Ltd
7.1.27.1 Company Overview
7.1.27.2 Product benchmarking
7.1.28 Shanghai Sunway Biotech Co., Ltd.
7.1.28.1 Company overview
7.1.28.2 Product benchmarking
7.1.29 Gensight Biologics S.A.
7.1.29.1 Company overview
7.1.29.2 Financial performance
7.1.29.3 Product benchmarking
7.1.29.4 Strategic initiatives
7.1.30 Transgene
7.1.30.1 Company overview
7.1.30.2 Financial performance
7.1.30.3 Product benchmarking
7.1.30.4 Strategic initiatives
7.1.31 Epeius Biotechnologies Corp.
7.1.31.1 Company overview
7.1.31.2 Financial performance
7.1.31.3 Product benchmarking
7.1.32 Calimmune, Inc.
7.1.32.1 Company overview
7.1.32.2 Product benchmarking
7.1.32.3 Strategic initiatives
7.1.33 Audentes Therapeutics, Inc.
7.1.33.1 Company overview
7.1.33.2 Financial performance
7.1.33.3 Product benchmarking
7.1.33.4 Strategic initiatives
7.1.34 American Gene Technologies
7.1.34.1 Company overview
7.1.34.2 Product Benchmarking
7.1.35 BioMarin Pharmaceuticals, Inc.
7.1.35.1 Company overview
7.1.35.2 Financial performance
7.1.35.3 Product benchmarking
7.1.35.4 Strategic initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novartis AG
  • Bluebird bio, Inc.
  • Spark Therapeutics, Inc.
  • REGENXBIO, Inc.
  • Audentes Therapeutics
  • Voyager Therapeutics
  • REGENXBIO, Inc.
  • Oxford BioMedica plc
  • Voyager Therapeutics
  • Human Stem Cells Institute
  • Dimension Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • Applied Genetic Technologies Corporation
  • Spark Therapeutics, Inc.
  • Bluebird Bio, Inc.
  • Novartis AG
  • AveXis, Inc.
  • Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
  • UniQure N.V.
  • Celgene Corporation
  • Shire Plc
  • Cellectis S.A.
  • Sangamo Therapeutics, Inc.
  • Orchard Therapeutics
  • Gilead Lifesciences, Inc.
  • Benitec Biopharma
  • Sibiono GeneTech Co., Ltd
  • Shanghai Sunway Biotech Co., Ltd.
  • Gensight Biologics S.A.
  • Transgene
  • Epeius Biotechnologies Corp.
  • Calimmune, Inc.
  • Audentes Therapeutics, Inc.
  • American Gene Technologies
  • BioMarin Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll